Inhibition of nucleotide oligomerization domain-like receptors containing pyrin domain 3 (NLRP3) inflammasome is a potential therapeutic strategy for NAFLD. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.